A Comprehensive Comparison Between Camelid Nanobodies and Single Chain Variable Fragments

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2021 Dec 5

PMID 34863296

Citations 71

Authors

Yasaman Asaadi

Fatemeh Fazlollahi Jouneghani

Sara Janani

Fatemeh Rahbarizadeh

Affiliations

Soon will be listed here.

Abstract

By the emergence of recombinant DNA technology, many antibody fragments have been developed devoid of undesired properties of natural immunoglobulins. Among them, camelid heavy-chain variable domains (VHHs) and single-chain variable fragments (scFvs) are the most favored ones. While scFv is used widely in various applications, camelid antibodies (VHHs) can serve as an alternative because of their superior chemical and physical properties such as higher solubility, stability, smaller size, and lower production cost. Here, these two counterparts are compared in structure and properties to identify which one is more suitable for each of their various therapeutic, diagnosis, and research applications.

Citing Articles

PET imaging of HIV-1 envelope protein gp120 using F-labeled nanobodies.

Martinez-Orengo N, Shah S, Lai J, Basuli F, Lyndaker A, Turner M iScience. 2025; 28(2):111795.

PMID: 39917021 PMC: 11800091. DOI: 10.1016/j.isci.2025.111795.

Targeting BCMA in multiple myeloma: designs, challenges, and future directions.

Hu Y, Xie Y, Wang X, Yang L, Geng H, Yi Z Cancer Immunol Immunother. 2025; 74(3):77.

PMID: 39891674 PMC: 11787132. DOI: 10.1007/s00262-024-03913-0.

Construction of Immune Single Domain Antibodies Library for Development of Specific Nanobodies Using Phage Display Strategy.

El-Kalamawy H, Awwad M, Diab T, Okasha H, Abdel-Kareim A, Marawan M Recent Pat Biotechnol. 2025; 19(1):69-83.

PMID: 39840412 DOI: 10.2174/0118722083275669231227063413.

An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

Wittich C, Ettich J, Hertell M, Ghosh Roy B, Roy B, Xu H J Biol Chem. 2025; 301(3):108205.

PMID: 39828098 PMC: 11872477. DOI: 10.1016/j.jbc.2025.108205.

Single chain fragment variable, a new theranostic approach for cardiovascular diseases.

Zahid R, Wang J, Cai Z, Ishtiaq A, Liu M, Ma D Front Immunol. 2024; 15:1443290.

PMID: 39735545 PMC: 11671482. DOI: 10.3389/fimmu.2024.1443290.

References

Chen J, He Q, Xu Y, Fu J, Li Y, Tu Z . Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein. Talanta. 2015; 147:523-30. DOI: 10.1016/j.talanta.2015.10.027. View

Tanaka T, Sewell H, Waters S, Phillips S, Rabbitts T . Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J Biol Chem. 2010; 286(5):3707-16. PMC: 3030373. DOI: 10.1074/jbc.M110.188193. View

Neri D, Sondel P . Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol. 2016; 40:96-102. PMC: 5215124. DOI: 10.1016/j.coi.2016.03.006. View

Dooley H, Flajnik M . Shark immunity bites back: affinity maturation and memory response in the nurse shark, Ginglymostoma cirratum. Eur J Immunol. 2005; 35(3):936-45. DOI: 10.1002/eji.200425760. View

Xu P, Raden D, Doyle 3rd F, Robinson A . Analysis of unfolded protein response during single-chain antibody expression in Saccaromyces cerevisiae reveals different roles for BiP and PDI in folding. Metab Eng. 2005; 7(4):269-79. DOI: 10.1016/j.ymben.2005.04.002. View

Harmsen M, De Haard H . Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007; 77(1):13-22. PMC: 2039825. DOI: 10.1007/s00253-007-1142-2. View

Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M . Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med. 2016; 8(366):366ra162. DOI: 10.1126/scitranslmed.aaf8463. View

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

Nguyen V, HAMERS R, Wyns L, Muyldermans S . Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J. 2000; 19(5):921-30. PMC: 305632. DOI: 10.1093/emboj/19.5.921. View

10.

Rahbarizadeh F, Ahmadvand D, Moghimi S . CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019; 141:41-46. DOI: 10.1016/j.addr.2019.04.006. View

11.

Berger M, Shankar V, Vafai A . Therapeutic applications of monoclonal antibodies. Am J Med Sci. 2002; 324(1):14-30. PMC: 7093874. DOI: 10.1097/00000441-200207000-00004. View

12.

Zhang W, Liu T, Wu M, Chen X, Han L, Shi Z . Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1. Acta Pharmacol Sin. 2021; 42(11):1921-1929. PMC: 8563870. DOI: 10.1038/s41401-020-00574-4. View

13.

Yang E, Shah K . Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Front Oncol. 2020; 10:1182. PMC: 7390931. DOI: 10.3389/fonc.2020.01182. View

14.

Weiss R, Verrips C . Nanobodies that Neutralize HIV. Vaccines (Basel). 2019; 7(3). PMC: 6789485. DOI: 10.3390/vaccines7030077. View

15.

Li D, Cui Y, Morisseau C, Gee S, Bever C, Liu X . Nanobody Based Immunoassay for Human Soluble Epoxide Hydrolase Detection Using Polymeric Horseradish Peroxidase (PolyHRP) for Signal Enhancement: The Rediscovery of PolyHRP?. Anal Chem. 2017; 89(11):6248-6256. PMC: 5611449. DOI: 10.1021/acs.analchem.7b01247. View

16.

Harmansa S, Hamaratoglu F, Affolter M, Caussinus E . Dpp spreading is required for medial but not for lateral wing disc growth. Nature. 2015; 527(7578):317-22. DOI: 10.1038/nature15712. View

17.

Borras L, Gunde T, Tietz J, Bauer U, Hulmann-Cottier V, Grimshaw J . Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem. 2010; 285(12):9054-66. PMC: 2838326. DOI: 10.1074/jbc.M109.072876. View

18.

Liu Y, Wang Y, Xing J, Li Y, Liu J, Wang Z . A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Des Devel Ther. 2018; 12:2645-2654. PMC: 6120566. DOI: 10.2147/DDDT.S166373. View

19.

Kontermann R . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009; 23(2):93-109. DOI: 10.2165/00063030-200923020-00003. View

20.

Lu Y, Liang K, Li X, Fan Z . Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer. 2007; 6:63. PMC: 2117021. DOI: 10.1186/1476-4598-6-63. View